Literature DB >> 34543610

Liver cirrhosis.

Pere Ginès1, Aleksander Krag2, Juan G Abraldes3, Elsa Solà4, Núria Fabrellas5, Patrick S Kamath6.   

Abstract

Cirrhosis is widely prevalent worldwide and can be a consequence of different causes, such as obesity, non-alcoholic fatty liver disease, high alcohol consumption, hepatitis B or C infection, autoimmune diseases, cholestatic diseases, and iron or copper overload. Cirrhosis develops after a long period of inflammation that results in replacement of the healthy liver parenchyma with fibrotic tissue and regenerative nodules, leading to portal hypertension. The disease evolves from an asymptomatic phase (compensated cirrhosis) to a symptomatic phase (decompensated cirrhosis), the complications of which often result in hospitalisation, impaired quality of life, and high mortality. Progressive portal hypertension, systemic inflammation, and liver failure drive disease outcomes. The management of liver cirrhosis is centred on the treatment of the causes and complications, and liver transplantation can be required in some cases. In this Seminar, we discuss the disease burden, pathophysiology, and recommendations for the diagnosis and management of cirrhosis and its complications. Future challenges include better screening for early fibrosis or cirrhosis, early identification and reversal of causative factors, and prevention of complications.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34543610     DOI: 10.1016/S0140-6736(21)01374-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  49 in total

1.  Total glucosides of paeony inhibits liver fibrosis and inflammatory response associated with cirrhosis via the FLI1/NLRP3 axis.

Authors:  Jie Zhang; Yiwei Fu; Bin Yang; Xiaoxing Xiang
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

Review 2.  Liver cirrhosis and immune dysfunction.

Authors:  Elda Hasa; Phillipp Hartmann; Bernd Schnabl
Journal:  Int Immunol       Date:  2022-09-06       Impact factor: 5.071

3.  Differences in anxiety among patients with liver cirrhosis with different compensation abilities.

Authors:  Mengdang Ou; Xiaozhen Guo; Ying Li; Haili Zhang; Ting Liu; Qun Liu; Wen Wei; Xiaoqing Luo; Yanyan Zhang
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

Review 4.  4D Flow MRI in the portal venous system: imaging and analysis methods, and clinical applications.

Authors:  Ryota Hyodo; Yasuo Takehara; Shinji Naganawa
Journal:  Radiol Med       Date:  2022-09-19       Impact factor: 6.313

5.  Liver scaffolds obtained by decellularization: A transplant perspective in liver bioengineering.

Authors:  Marlon Lemos Dias; Bruno Andrade Paranhos; Regina Coeli Dos Santos Goldenberg
Journal:  J Tissue Eng       Date:  2022-06-20       Impact factor: 7.940

6.  Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review.

Authors:  Catharina J Alberts; Gary M Clifford; Damien Georges; Francesco Negro; Olufunmilayo A Lesi; Yvan J-F Hutin; Catherine de Martel
Journal:  Lancet Gastroenterol Hepatol       Date:  2022-05-14

Review 7.  Clinical Application of Induced Hepatocyte-like Cells Produced from Mesenchymal Stromal Cells: A Literature Review.

Authors:  Yanina Bogliotti; Mark Vander Roest; Aras N Mattis; Robert G Gish; Gary Peltz; Robin Anwyl; Salah Kivlighn; Eric R Schuur
Journal:  Cells       Date:  2022-06-22       Impact factor: 7.666

8.  Increased Serum Levels of sCD206 Are Associated with Adverse Prognosis in Patients with HBV-Related Decompensated Cirrhosis.

Authors:  Yue Zhang; Nanxi Xiao; Qi Liu; Yuan Nie; Xuan Zhu
Journal:  Dis Markers       Date:  2022-05-25       Impact factor: 3.464

9.  LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries.

Authors:  Isabel Graupera; Maja Thiele; Ann T Ma; Miquel Serra-Burriel; Judit Pich; Núria Fabrellas; Llorenç Caballeria; Robert J de Knegt; Ivica Grgurevic; Mathias Reichert; Dominique Roulot; Jörn M Schattenberg; Juan M Pericas; Paolo Angeli; Emmanuel A Tsochatzis; Indra Neil Guha; Montserrat Garcia-Retortillo; Rosa M Morillas; Rosario Hernández; Jordi Hoyo; Matilde Fuentes; Anita Madir; Adrià Juanola; Anna Soria; Marta Juan; Marta Carol; Alba Diaz; Sönke Detlefsen; Pere Toran; Céline Fournier; Anne Llorca; Phillip N Newsome; Michael Manns; Harry J de Koning; Feliu Serra-Burriel; Fernando Cucchietti; Anita Arslanow; Marko Korenjak; Laurens van Kleef; Josep Lluis Falcó; Patrick S Kamath; Tom H Karlsen; Laurent Castera; Frank Lammert; Aleksander Krag; Pere Ginès
Journal:  BMC Public Health       Date:  2022-07-19       Impact factor: 4.135

Review 10.  A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Hepatic Encephalopathy and Clostridioides difficile Infection in Patients With Cirrhosis.

Authors:  Kyaw Min Tun; Annie S Hong; Kavita Batra; Yassin Naga; Gordon Ohning
Journal:  Cureus       Date:  2022-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.